Sleep study for baby hemangioma drug stopped early
NCT ID NCT05479123
First seen Mar 18, 2026 · Last updated Jun 20, 2026 · Updated 15 times
Summary
This study looked at whether giving propranolol two or three times a day affects sleep in infants with hemangiomas (benign blood vessel growths). It enrolled 52 infants and compared sleep awakenings and total awake time at night. The study was terminated early, so findings are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFANTILE HEMANGIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The University of Texas Health Science Center at Houston
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
propranolol
What this could lead to
If successful, this could help doctors choose a dosing schedule that causes fewer sleep disruptions for infants taking propranolol for hemangiomas.
What could go wrong
This was a small, early-terminated Phase 4 study, so results are limited and may not apply broadly. The study did not reach its planned enrollment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.